EP3672577A1 - Produit de combinaison pour aider a retrouver la forme - Google Patents
Produit de combinaison pour aider a retrouver la formeInfo
- Publication number
- EP3672577A1 EP3672577A1 EP17783715.0A EP17783715A EP3672577A1 EP 3672577 A1 EP3672577 A1 EP 3672577A1 EP 17783715 A EP17783715 A EP 17783715A EP 3672577 A1 EP3672577 A1 EP 3672577A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- biotin
- combination product
- nicotinamide
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Definitions
- the subject of the present invention is a combination product comprising, as active substances, at least vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin and folic acid, or a bioequivalent compound of these to help regain shape.
- the invention finally relates to a composition comprising vitamins in the form of a chewing gum for a food supplement. This composition allows a better compliance of the patient with respect to compositions that are not in the form of chewing gums.
- the dosage forms proposed for the multivitamin products are generally in the form of syrup, capsules or tablets to swallow or chew. These dosage forms need to be taken with a glass of water for swallowing tablets or capsules or having a spoon or cup for syrups. They can also be disappointing from a taste point of view. This leads, and this is particularly true when the treatment is intended for children, poor compliance, that is to say, poor monitoring of treatment.
- the Applicant has therefore wished to develop a product that can be used by a large population, which contains no animal products, no preservatives and no lactose.
- the Applicant has developed, and it is the object of the present invention, a combination product comprising, as active substances, at least vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin, folic acid, or a bioequivalent compound of these help shape recovery.
- help to find the shape means in the context of the present invention, help to find the energy, no longer feel tired.
- Such a product thus makes it possible to overcome a deficiency in vitamin intake with a composition that contains no animal product, lactose or preservatives.
- the product of the present invention has a galenic adapted to adults and children.
- the product according to the present invention has a pleasant taste and odor.
- the present invention relates to a combination product comprising, as active substances, at least vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin, folic acid, or a bioequivalent compound of these help shape recovery.
- the combination product according to the invention comprises, in addition to vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin, folic acid, active substances:
- Vitamins and minerals such as, for example, vitamins A, K, B12, zinc, iron, copper, manganese, selenium, calcium, iodine or magnesium
- the combination product of the invention is characterized in that vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin, folic acid are present in a gum chewable composition
- a gum chewable composition comprising: from 0.2 to 1 mg, preferably from 0.3 to 0.7 mg of vitamin B1 from 0.2 to 1 mg, preferably from 0.4 to 0.8 mg of vitamin B2 from 1 to 6 mg preferably 2 to 4 mg of vitamin B5 of 0.2 to 1 mg, preferably 0.4 to 0.8 mg of vitamin B6 of 20 to 100 mg, preferably 30 to 60 mg of vitamin C of 1 to 5 ⁇ g of preferably 2 to 4 ⁇ g of vitamin D3 of 1 to 12 mg, preferably 4 to 6 mg of vitamin E of 5 to 15 mg, preferably 6 to 10 mg of nicotinamide of 10 to 50 ⁇ g, preferably 15 to 30 ⁇ g of biotin of 50 at 200 ⁇ g, preferably 75 to 150 ⁇ g of folic acid in a physiologically acceptable medium.
- the combination product is characterized in that the active ingredients, that is to say vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin, folic acid or a bioequivalent compound thereof are in a medium suitable for oral administration.
- the suitable medium is a solid medium.
- the combination product is in the form of chewing gum.
- Vitamin Bl has demonstrated that the combination of vitamin B1, B2, B5, B6, C, D3, E, nicotinamide, biotin and folic acid has a synergistic effect to help find the form.
- Thiamine or vitamin B1 is a metabolic precursor of thiamine pyrophosphate (TPP), a coenzyme essential for certain decarboxylases.
- TPP thiamine pyrophosphate
- thiamine is a water-soluble vitamin of the family B vitamins they must find in their diet.
- it is synthesized by bacteria, plants and fungi. It is essential for the conversion of carbohydrates into energy by the Krebs cycle and is necessary for the proper functioning of the nervous system and muscles. It is indeed essential for the transformation of pyruvate produced by glycolysis and toxic for the nervous system.
- dietary vitamin B deficiency 1 causes beriberi and may also cause encephalopathy of Gayet-Wernicke.
- composition according to the present invention of 0.2 to 1 mg preferably 0.3 to 0.7 mg of vitamin B1.
- Vitamin B2 corresponding to riboflavin, or lactoflavin, is a water-soluble vitamin required for the synthesis of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), two essential cofactors for flavoproteins. Vitamin B2 plays an important role in transforming simple foods (carbohydrates, fats and proteins) into energy. It is involved in muscle repair metabolism.
- Riboflavin is naturally found in asparagus, popcorn, bananas, persimmons, okra, chard, cheese, milk, yoghurt, meat, eggs, fish and eggs.
- green beans each of which contains at least 0.1 mg of vitamin B per 85-300g.
- Other sources are green leafy vegetables, liver, kidneys, legumes, tomatoes, yeasts, mushrooms and almonds.
- composition according to the present invention comprises from 0.2 to 1 mg, preferably 0.4 to 0.8 mg of vitamin B2.
- Vitamin B5 corresponding to pantothenic acid, is a water-soluble vitamin. It is a metabolic precursor of Coenzyme A, essential for the synthesis and metabolism of proteins, carbohydrates and lipids.
- the etnic root comes from ⁇ (p ⁇ tothothen), which in Greek means "everywhere”: this vitamin is found in almost all foods. However, it is found in particularly concentrated proportions in sprouts and whole grains and in stinging nettle varieties. Royal jelly is one of the richest known natural products in vitamin B5.
- Pantothenic acid consists of a molecule of pantoic acid and a molecule of ⁇ -alanine, linked by an amide function.
- vitamin B5 promotes growth and resistance of the skin and mucous membranes. It is necessary for the metabolism of carbohydrates, lipids and proteins and participates in the synthesis of certain hormones. Pantothenic acid is destroyed by heat in aqueous solution.
- composition according to the present invention comprises from 1 to 6 mg, preferably 2 to 4 mg of vitamin B5.
- Vitamin B6 is a water-soluble vitamin that exists in several forms, pyridoxal phosphate being its biologically active form, as a cofactor involved in several reactions of amino acid metabolism, including transaminations, deaminations and decarboxylations. Pyridoxal phosphate is also involved in the hydrolysis reaction of glycogen to glucose.
- Vitamin B6 is known in seven different forms, interconvertible between them except the last one:
- pyridoxine the form in which vitamin B6 is administered as a dietary supplement
- PNP pyridoxine phosphate
- PDP pyridoxal phosphate
- PM pyridoxamine
- PA 4-pyridoxic acid
- Vitamin B6 participates in the transformation of tryptophan into vitamin B3, and the metabolism of lipids and amino acids (decarboxylation and transamination). Pyridoxal phosphate allows the conversion of glycogen to glucose (Glucose-1-Phospate) by Glycogen phosphorylase.
- Vitamin B6 also participates in the biosynthesis of serotonin.
- composition according to the present invention comprises 0.2 to 1 mg, preferably 0.4 to 0.8 mg of vitamin B6.
- Vitamin C is a water-soluble, heat-sensitive vitamin and light that plays an important role in the metabolism of humans and many other mammals. Chemically speaking, it is L-ascorbic acid, one of the stereoisomers of ascorbic acid, and its salts, ascorbates. The most common are sodium ascorbate and calcium ascorbate.
- Vitamin C is an enzymatic cofactor involved in a number of physiological reactions (hydroxylation). It is required in the synthesis of collagen and red blood cells and contributes to the immune system. It also plays a role in the metabolism of iron as a promoter of its absorption; its use is therefore not recommended in patients with iron overload and particularly hemochromatosis. In oxidized form (dehydroascorbic acid), it crosses the blood-brain barrier to access the brain and several organs with a high concentration of vitamin C.
- composition according to the present invention comprises from 20 to 100 mg, preferably 30 to 60 mg of vitamin C.
- Cholecalciferol is a form of vitamin D, also called vitamin D3.
- Vitamin D3 is a secosteroid rather related to testosterone, cholesterol and cortisol.
- Vitamin D has a double origin: it is brought by the diet and synthesized by the body in the skin under the action of UVB rays of the sun.
- Subjects with low sun exposure may have more or less vitamin D deficiencies. Clear-skinned people synthesize vitamin D faster than those with darker skin, and therefore require less exposure time. long to convert the precursors of vitamin D produced by the liver into vitamin D.
- the amount of vitamin D that the skin can produce is limited; prolonged exposure to sunlight (more than 30 minutes for a person with fair skin, up to three hours for people with dark skin) does not increase the amount of cholecalciferol produced by the body.
- an exposure of 10 to 15 minutes a few times a week is enough to cover the needs of vitamin D3. Vitamin D manufactured by the skin is stored in the liver, muscle and fatty tissue and used on demand during winter periods.
- vitamin D2 or ergocalciferol produced by plants Two forms of vitamin D exist: vitamin D2 or ergocalciferol produced by plants and vitamin D3 or cholecalciferol produced by animals, as well as by some lichens. In humans, these two forms are converted into 1,25-dihydroxyvitamin D (commonly known as vitamin D), their main active metabolite.
- vitamin D The essential function of vitamin D is to increase the absorption capacity of the intestine for calcium and phosphorus which allows: 1. to ensure optimal mineralization of mineralized tissues, including bone, cartilage and teeth;
- vitamin D deficiency The clinical signs of vitamin D deficiency are: osteomalacia and rickets at the bone level, decreased muscle tone, tetanus attacks and seizures (in connection with hypocalcemia) and sometimes anemia.
- vitamin D deficiency is a breeding ground for bone loss (and thus osteoporosis), and depression (as confirmed by a Dutch study mentioned in Archives of General Psychiatry (May 2008)) .
- vitamin D The recommended dietary intakes of vitamin D have been defined considering that the endogenous production covers 50 to 70% of the daily needs in this vitamin.
- a limited number of foods contain significant amounts of vitamin D. Indeed, these levels are closely related to the presence of fat in foods.
- the best sources of vitamin D are fatty sea fish, whatever their method of preparation and preservation (cooking with water, smoking, canning, grilling): herring, salmon, sardines, mackerel for example.
- Egg yolk, dairy products, soy and its derivatives (tofu and milk soybeans for example) and certain mushrooms (with great differences depending on the variety) are also sources of vitamin D.
- Small amounts of vitamin D are also provided by meat, offal and pâtés. Lean fish (skate, sole, hake ...) are lacking.
- Some lichens also produce cholecalciferol (vitamin D3), and are used to produce vegetable food supplements in this vitamin.
- composition according to the present invention comprises from 1 to 5 ⁇ g, preferably from 2 to 4 ⁇ g of vitamin D3.
- Vitamin E is a fat-soluble vitamin covering a set of eight organic molecules, four tocopherols and four tocotrienols. The most biologically active form is ⁇ -tocopherol, the most abundant in the diet being ⁇ -tocopherol. These molecules are present in large quantities in vegetable oils. They act, in parallel with vitamin C and glutathione, essentially as antioxidants against reactive derivatives of oxygen produced in particular by the oxidation of fatty acids.
- Vitamin E exists in eight natural forms, four tocopherols and four tocotrienols: ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol (apoptotic properties), ⁇ -tocotrienol .
- the body continually produces free radicals, highly reactive compounds with single electrons. Free radicals damage cellular components as diverse as proteins, lipids or DNA. Radical reactions propagate in a chain: molecules destabilized by a single electron become in turn free radicals. The role of antioxidants is to stop this process by neutralizing free radicals, to reduce their harmfulness. Thus, vitamin E has the ability to capture and stabilize (by resonance) the single electron of free radicals.
- the radical-bearing tocopherol may react with a new free radical to form a neutral species, or be regenerated by vitamin C, glutathione or coenzyme Q10.
- Vitamin E mainly plays its role as an antioxidant in biological membranes. Mitochondria, which generate free radicals, contain high levels of vitamin E in their lipid membrane, consisting of polyunsaturated fatty acids and subjected to oxidative stress. Vitamin E deficiency causes neuromuscular problems such as myopathies (degeneration of muscle tissue), disorders of the retina or the immune system 1.
- vitamin E prevents the excessive aggregation of platelets responsible for thrombosis, has a protective action on red blood cells and could prevent, by this means cardiovascular diseases of atheromatous origin.
- composition according to the present invention comprises from 1 to 12 mg, preferably 4 to 6 mg of vitamin E.
- Nicotinamide also known as niacinamide, is a derivative of nicotinic acid. Nicotinamide is a water-soluble vitamin and is part of the vitamin B group. Nicotinic acid, also known as niacin, is converted to nicotinamide in vivo. Although both have the same functions as vitamins, nicotinamide does not have the pharmacological and toxic effects of niacin. Thus nicotinamide does not reduce cholesterol levels.
- the composition according to the present invention comprises 5 to 15 mg, preferably 6 to 10 mg of nicotinamide.
- Biotin is a water-soluble vitamin. Biotin is a coenzyme that participates in the metabolism of fatty acids, carbohydrates and amino acids, as well as the biosynthesis of vitamins B9 and B12. It is therefore found, from a biological point of view, in all living species. Dietary, it is found in particular in whole grains, liver, eggs and milk, but also soy, hazelnuts, yeasts and smaller amounts in other foods.
- Biotin is needed for cell growth, fatty acid production, and metabolism of fats and amino acids. It plays a role in the Krebs cycle which is the biochemical process by which energy is produced during aerobic respiration. Biotin not only participates in various metabolic reactions, but also helps in the transfer of carbon dioxide. Biotin is also helpful in maintaining a constant level of blood sugar (blood sugar). Biotin is often recommended to reinforce hair and nails. As a result, it is a component of many cosmetics and health products for hair and skin.
- bioavailability of biotin may be low or variable depending on the type of food consumed.
- biotin exists in foods in the form of proteins or biocytin. Proteolysis by protease is necessary before absorption. This process promotes the release of biotin from biocytin and proteins.
- Corn biotin is readily available, but most cereals have a biotin bioavailability of 20-40%.
- a possible explanation for the great variability in the bioavailability of biotin lies in the ease with which an organism breaks the biotin-protein linkage of food, in the clear if it has the enzyme capable of breaking these links.
- Biotin supplements are often recommended as a natural way to combat the problem of hair loss in children and adults.
- the signs and symptoms of biotin deficiency include hair loss that progresses in severity to the loss of eyelashes and eyebrows in severely deficient subjects.
- composition according to the present invention comprises from 10 to 50 ⁇ g, preferably from 15 to 30 ⁇ g of biotin.
- Vitamin B9 is a water-soluble vitamin.
- Folic acid is the metabolic precursor of a coenzyme, tetrahydrofolate (FH4 or THF), involved in particular in the synthesis of nucleic bases, purines and pyrimidines, constituting the nucleic acids (DNA and RNA) of the genetic material.
- THF is also involved in the synthesis of amino acids such as methionine, histidine and serine.
- the folates must previously be reduced, that is to say hydrogenated, to dihydrofolate (FH2) and then tetrahydrofolate (FH4), by folate reductase, and dihydrofolate reductase respectively.
- the tetrahydrofolate then receives a methylene group from one of the three "carbon donors" (serine, glycine, formaldehyde) to form 5,10-methylenetetrahydrofolate (5,10-CH2-FH4).
- Serine is the most commonly used donor in humans.
- a deficiency of folate essentially causes anemia which is characterized by increased size of red blood cells (macrocytic anemia) and the appearance of megaloblasts in the bone marrow.
- the term megaloblastic anemia is usually restricted to vitamin B12 or folate deficiencies, but any disruption in the synthesis of purines, pyrimidines, and proteins can cause megaloblastic anemia.
- folic acid In the treatment of megaloblastic anemias, both folic acid and vitamin B12 have their place. But folic acid alone can not prevent or cure neurological complications (neuroanemic syndrome).
- vitamin B12 catalyzes the synthesis of thymidine, an important substance for the metabolism of nucleotides. Thymidine is formed from thymine, the synthesis of which is catalyzed by folic acid. It is for this reason that folic acid is combined with vitamin B12 for the treatment of macrocytic normochromic anemias of megaloblastic type.
- composition according to the present invention comprises from 50 to 200 ⁇ g, preferably 75 to 150 ⁇ g of folic acid.
- a physiologically acceptable medium is a medium having no toxic or detrimental effect under the conditions of use and inert with respect to the active ingredients of the combination product.
- a medium may for example comprise different adjuvants according to its purpose therapeutic or cosmetic, such as, but not limited to, flavors, dyes, fillers, preservatives, diluents, wetting or suspending agents, etc.
- Such media may also allow immediate, modified or delayed release of either active ingredient.
- the physiologically acceptable medium may be composed of texturants, dyes, flavors, sugar (s).
- Textturizers means compounds that modify the texture of the products in which they are incorporated. Examples of texturants are: guar and carob flour; gum arabic, xanthan and gellan; carrageenans; starches (native or modified); microcrystalline cellulose; pectin; alginates (E400 to E405); agar-agar; and their mixtures. In the context of the present invention, the texturizer will preferably be pectin.
- dyes compounds of natural or synthetic origin capable of conferring on their own a coloration to the composition.
- examples of food dyes are known in Europe under the codes E100 to E180.
- use will preferably be made of dyes of natural origin such as: E140 (or chlorophylls), E 163 (or anthocyanins) , E 160c (or paprika extract) or E100 (or curcumin).
- flavors compounds of natural or synthetic origin capable alone to change the taste of the composition.
- aromas are apricot, pineapple, banana, blackcurrant, cherry, lemon, lime, strawberry, raspberry, passion fruit, tangerine, mint, orange , pistachio, pear, licorice, rose, anise, blueberry, cinnamon, ginger, grapefruit, apple, kiwi, lychee, melon, coconut, peach, gooseberry, guava, grenadine, mango, blackberry, papaya, vanillin, natural vanilla extract, essential oils and mixtures thereof.
- it will preferably use the natural aroma of strawberry, apple, orange and / or lemon.
- sugar or sugar is understood to mean any sweetening carbohydrate, preferably glucose syrup, sucrose, glucose, fructose, invert sugar, honey, maltose, polyol or mixtures thereof.
- sugar used is preferably glucose syrup in combination with sucrose. Additional asset (s)
- the combination product may include, by way of example, vitamins, mineral salts, essential amino acids, essential fatty acids, trace elements, various plant extracts, fibers, antioxidants, flavonoids.
- such additional asset may be intended to enhance the desired effect as described above.
- water-soluble vitamins present in the chewing gum prepared according to the invention are especially: vitamin B12 (cobalamin).
- examples of fat-soluble vitamins present in the chewing gum prepared according to the invention include vitamin A (retinol) and vitamin K (phylloquinone).
- antioxidants such as curcuminoids; carotenoids, especially chosen from beta.-carotene, astaxanthin, zeaxanthin, lutein or compounds containing them, such as goji berries; polyphenol compounds, flavonoids such as catechins; proanthocyanidins, anthocyanins, OPCs (procyanidolic oligomers); ubiquinones; coffee extracts containing polyphenols and / or diterpenes; chicory extracts; ginkgo biloba extracts; grape extracts rich in proanthocyanidins; chili extracts; soy extracts; Cocoa ; the grenade ; the Emblica; CoenzymeQ10; selenium, - minerals, such as zinc, calcium, copper, iron, iodine, manganese, selenium, chromium (III),
- amino acids especially sulfur-containing amino acids, such as glutathione precursors, the amino acids of selenium, citrulline, phytosterols, resveratrol, hesperidin, neohesperidin, orthosilicic acid, monomethylsilanetriol, and mixtures thereof.
- a combination product according to the invention is administered orally.
- the appropriate forms for the oral route are chewing gums.
- a physiologically acceptable vehicle such as pectin, starch, glucose syrup and sucrose.
- This composition is obtained by mixing the various compounds according to the methods conventionally used for this type of preparation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/001007 WO2019037829A1 (fr) | 2017-08-23 | 2017-08-23 | Produit de combinaison pour aider a retrouver la forme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3672577A1 true EP3672577A1 (fr) | 2020-07-01 |
Family
ID=60083238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17783715.0A Withdrawn EP3672577A1 (fr) | 2017-08-23 | 2017-08-23 | Produit de combinaison pour aider a retrouver la forme |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3672577A1 (fr) |
| WO (1) | WO2019037829A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569477A (en) * | 1995-04-28 | 1996-10-29 | Mccready Consumer Products, Inc. | Chewing gum containing vitamins or other active materials |
| US6660293B2 (en) * | 2001-06-29 | 2003-12-09 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| AU2003300167B2 (en) * | 2003-12-31 | 2010-09-16 | K-Pax Vitamins, Inc. | Nutrient compositions and methods for enhanced effectiveness of the immune system |
| US20150139972A1 (en) * | 2013-11-18 | 2015-05-21 | Gerald Haase | Micronutrient Formulation For Concussive Head Injuries |
-
2017
- 2017-08-23 WO PCT/EP2017/001007 patent/WO2019037829A1/fr not_active Ceased
- 2017-08-23 EP EP17783715.0A patent/EP3672577A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019037829A1 (fr) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6579544B1 (en) | Method for supplementing the diet | |
| US20060115556A1 (en) | Nutritional supplement drink containing xanthone extracts | |
| US20060115555A1 (en) | Nutritional supplements containing xanthone extracts | |
| EP2117356B1 (fr) | Composition dietetique antioxydante a base de fruits et legumes, son procede d'obtention et utilisation de la composition | |
| NO323353B1 (no) | Sportsdrikk omfattende mikronaeringsstoffer og levedyktige lactobacilli | |
| US20140045874A1 (en) | Prevention of alcohol reaction with dietary supplements | |
| US20240285704A1 (en) | Compositions comprising organic mineral chelates, niacinamide, and hemp oil and uses thereof for neuroprotection, cardioprotection, detoxification, immune support, and anti-aging | |
| EP1302115A1 (fr) | Utilisation de cystathionine | |
| KR20110119305A (ko) | 타우린, 비타민류, 로얄젤리, 홍삼, 구기자, 글루메이트 (탈지미강, 미베아) 및 애플 에센스를 주성분으로 함유하는 기능성 음료조성물 | |
| JP2024536891A (ja) | 栄養組成物 | |
| WO2020260506A1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l'organisme | |
| TWI715550B (zh) | 口服產品 | |
| WO2025040478A1 (fr) | Produit de combinaison à libération prolongée à base de magnésium, vitamine b6 et hpmc pour aider à la relaxation et diminuer l'irritabilite | |
| EP3672577A1 (fr) | Produit de combinaison pour aider a retrouver la forme | |
| WO2021023600A1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l'organisme et à retrouver la forme | |
| FR3138302A1 (fr) | Produit de combinaison adapté aux besoins de l’adulte | |
| WO2021116188A1 (fr) | Produit de combinaison, contribuant au bien-etre de la femme enceinte, comprenant epa, dha, des vitamines et des mineraux | |
| WO2023006854A1 (fr) | Produit de combinaison pour aider à retrouver la forme | |
| EP2452577B1 (fr) | Solution aqueuse de phytine et utilisation de ladite solution pour la préparation d'un complément alimentaire liquide ou d'une composition cosmétique | |
| WO2020260500A1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l'organisme | |
| WO2023006858A1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l'organisme, à la protection des cellules contre le stress oxydatif et réduire la fatigue | |
| WO2023006857A1 (fr) | Produit de combinaison pour stimuler le fonctionnement des cellules hépatiques et faciliter l'endormissement | |
| WO2023144289A1 (fr) | Utilisation d'un mélange de flavanols pour augmenter la concentration de la forme active de la vitamine d, le calcitriol. | |
| FR3055087B1 (fr) | Composition alimentaire a base d'extrait de spiruline, d'extrait de fruit et de magnesium | |
| FR3152119A1 (fr) | Produit de combinaison pour aider à la relaxation et diminuer l’irritabilité |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200224 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20221020 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20250522 |